OKUR reports financial results, advancing leads
OnKure Therapeutics reported Q2 2026 results with $176M cash runway until 2029, while advancing PI3Kα pan-mutant inhibitor pipeline candidates for IND submissions in 1H 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day